tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

LakeShore Biopharma Announces Going-Private Transaction Agreement

Story Highlights
LakeShore Biopharma Announces Going-Private Transaction Agreement

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

LakeShore Biopharma ( (LSBCF) ) just unveiled an update.

On November 4, 2025, LakeShore Biopharma announced a definitive agreement for a going-private transaction through a merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. The merger values the company at approximately $37 million, offering a 15.4% premium over the closing share price on August 15, 2025. The transaction, expected to close in the first quarter of 2026, will result in LakeShore Biopharma becoming a privately held company, with its shares no longer listed on the OTC Pink Open Market. This strategic move is supported by major shareholders and aims to enhance the company’s operational flexibility and long-term growth potential.

The most recent analyst rating on (LSBCF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSBCF Stock Forecast page.

Spark’s Take on LSBCF Stock

According to Spark, TipRanks’ AI Analyst, LSBCF is a Neutral.

LakeShore Biopharma’s overall stock score is primarily impacted by its financial performance, which is challenged by persistent losses and negative cash flows. Technical analysis indicates a bearish trend, further weighing on the score. The lack of profitability and dividend yield results in a low valuation score. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on LSBCF stock, click here.

More about LakeShore Biopharma

LakeShore Biopharma, formerly known as YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer. The company operates in China, Singapore, and the Philippines and is known for its proprietary PIKA® immunomodulating technology platform.

Average Trading Volume: 48,908

Technical Sentiment Signal: Sell

Current Market Cap: $30.09M

For an in-depth examination of LSBCF stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1